For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
6
views
48
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      216
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES Trial): protocol of a prospective, multicentre observational trial.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with an overall 5-year survival of approximately 8%. The success in reducing the mortality rate of PDAC is related to the discovery of new therapeutic agents, and to a significant extent to the development of early detection and prevention programmes. Patients with new-onset diabetes mellitus (DM) represent a high-risk group for PDAC as they have an eightfold higher risk of PDAC than the general population. The proposed screening programme may allow the detection of PDAC in the early, operable stage. Diagnosing more patients in the curable stage might decrease the morbidity and mortality rates of PDAC and additionally reduce the burden of the healthcare.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: not found
          • Article: not found

          Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

          Yoav Benjamini, Yosef Hochberg (1995)
          Article 0 comments Cited 24135 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer statistics, 2016.

            Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal (2016)
            Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States. Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses. The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012. Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease. Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia. Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.
            Article 0 comments Cited 1863 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

              Lola Rahib, Benjamin D Smith, Rhonda Aizenberg … (2014)
              Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the average annual percentage changes in incidence and death rates. Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, respectively. Lung cancer is projected to remain the top cancer killer throughout this time period. However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, respectively. Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future. ©2014 American Association for Cancer Research.
              Article 0 comments Cited 1581 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): BMJ Open
                Title: BMJ open
                Publisher: BMJ
                ISSN (Electronic): 2044-6055
                ISSN (Print): 2044-6055
                Publication date (Electronic): Nov 19 2020
                Volume: 10
                Issue: 11
                Affiliations
                [1 ] First Department of Medicine, University of Szeged Faculty of Medicine, Szeged, Hungary.
                [2 ] Tegeler Weg 33, 10589, Metanomics Health GmbH, Berlin, Germany.
                [3 ] Department of Internal Medicine, Semmelweis University of Medicine, Budapest, Hungary.
                [4 ] Ilona Tóth Outpatient Clinic, Budapest, Hungary.
                [5 ] Institute for Translational Medicine, University of Pécs Medical School, Pécs, Hungary.
                [6 ] János Szentágothai Research Center, University of Pécs, Pécs, Hungary.
                [7 ] Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.
                [8 ] MTA-SZTE Translational Gastroenterology Research Group, Szegedi Tudomanyegyetem, Szeged, Hungary.
                [9 ] Medical School, University of Szeged Faculty of Medicine, Szeged, Hungary.
                [10 ] First Department of Medicine, University of Szeged, Szeged, Hungary czako.laszlo@med.u-szeged.hu.
                Article
                Publisher Item ID: bmjopen-2020-037267
                DOI: 10.1136/bmjopen-2020-037267
                PMC ID: 7678370
                PubMed ID: 33444177
                SO-VID: db7ad147-f0b9-4bcf-8db1-5b73c51ab4dc
                History

                Keywords: general diabetes,preventive medicine,protocols & guidelines,pancreatic disease
                Data availability:
                Keywords: general diabetes, preventive medicine, protocols & guidelines, pancreatic disease

                Comments

                Comment on this article

                scite_

                Similar content216

                See all similar

                Cited by3

                See all cited by

                Most referenced authors1,247

                See all reference authors